Baxter International (BAX) is seeing bullish earnings projections. The current full-year Zacks Consensus Estimate of $3.79 per share was increased from $3.77 over the past 3 months. For 2010, the forecast jumped from $4.24 to $4.28 over the same time frame.

Company Description

Baxter International develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, cancer, infectious diseases, kidney disease, trauma and other chronic and acute medical conditions.

As a global diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide. The company’s products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors’ offices, clinical and medical research laboratories, and by patients at home under physician supervision. Baxter manufactures products in 26 countries and sells them in more than 100 countries.

Higher Forecasts

The company is seeing bullish earnings projections. The current full-year Zacks Consensus Estimate of $3.79 per share was increased from $3.77 over the past 3 months. For 2010, the forecast jumped from $4.24 to $4.28 over the same time frame.

Baxter’s 2009 earnings guidance ranges between $3.76 and $3.80 per share.

Recent Events

The company recently discussed its long-term financial objectives, growth opportunities and various research and development (R&D) programs at its recently concluded Investor Conference in Chicago.

Rewarding Shareholders

In late July, Baxter declared a quarterly dividend of 26 cents per share, which was paid out on October 1. Baxter rewards shareholders with an industry-leading dividend yield of 2%.

A Solid Quarter

In mid-July, the company posted second-quarter earnings of 96 cents per share, topping the consensus estimate by 2% and surpassing the previous year’s 85 cents.

Worldwide sales of $3.1 billion slipped by 2%. Excluding the impact of foreign currency, worldwide sales were up 8%. U.S. sales climbed 7% to $1.3 billion. International sales dipped by 8% to $1.8 billion. Excluding the impact of foreign currency, international sales increased 9%.

Zacks Investment Research
View original at: Zacks.com News Feed

1. (BAX) Baxter International Discussed Long-Term GoalsBaxter International Inc. (BAX) discussed its long-term financial objectives, growth opportunities and various research and...
2. (BAX) Baxter International Fails to Deliver Swine Flu VaccineBaxter International Inc. (BAX) has failed to deliver on its pledge to the U.K. government...
3. ($BAX) Baxter International – ROE of 35%, soaring past the industry average of 8%$Baxter International Inc. (BAX) recently posted second-quarter earnings of 96 cents per share, topping the...
4. (BAX) Baxter International Inc. – Growth And Income – Zacks Rank BuyBaxter International Inc. (BAX) is seeing upbeat estimates ahead of announcing second-quarter results in early...
5. (BAX) Baxter International, Inc. – Growth And Income – Zacks Rank BuyBaxter International Inc. (BAX) recently declared a quarterly dividend of 26 cents per share, noting...
6. (BAX) Baxter International – ROE of 31% more than doubles the industry average of 12%Baxter International Inc. (BAX) recently reported record results for 2008, surpassing its guidance. The company...

Search Posts by Tag: BAX | Baxter International Inc | Healthcare

RSS Feeds by Tag: BAX | Baxter International Inc | Healthcare |

Other Posts by: vitalstocks | RSS Feed for this author